...
首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >FLOATING DRUG DELIVERY SYSTEM AS AN APPROACH TO INCREASE THE GASTRIC RETENTION OF METHOTREXATE: FORMULATION AND EVALUATION
【24h】

FLOATING DRUG DELIVERY SYSTEM AS AN APPROACH TO INCREASE THE GASTRIC RETENTION OF METHOTREXATE: FORMULATION AND EVALUATION

机译:漂浮药物输送系统作为增加甲氨蝶呤胃保留的一种方法:配方和评估

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The objective of the present study is to develop and characterize floating microspheres of methotrexate, which after oral administration could prolong the gastric residence time and increase the bioavailability of the drug, in order to provide the sustained release to minimize the dose dependent side effects as well as to improve patient compliance. Another aim is to investigate drug release at slight higher pH, which is due to frequent administration of water to make dosage form floating. The porous microspheres containing (1) methotrexate – antineoplastic agent, (2) casein – emulsifier which incorporate air bubbles at interface and (3) pectin – polymer, by emulsification extraction method and to evaluate gastro retentive and controlled release properties at pH 4.0. The effects of various process variables on the particle size, % buoyancy and % drug entrapment were assessed by 32full factorial design and concluded by using two way ANOVA and polynomial regression methods. Process variables had considerable effect on all dependent variables. The microspheres were found to be regular in shape with rough surface. Microsphere formulation M9 showed particle size 59.60±0.95μm, buoyancy 82.0±0.27%, and %drug entrapment 97.54±0.53%. In vitro drug release study was done results calculated by PCP disso vi software revealed best fitted model for M9 as Korsmayer Peppas model and drug release in Fickian manner. In vitro cytotoxicity study on KATO III gastric cell line revealed methotrexate microspheres had greater cytotoxic effects on cell line in comparison to pure drug solution. In vivo gamma scintigraphy studies were done using albino mice showed more than 8 hrs retention in upper gastro intestinal tract
机译:本研究的目的是开发和表征甲氨蝶呤的漂浮微球,口服后可延长胃停留时间并增加药物的生物利用度,以提供持续释放以最大程度降低剂量依赖性副作用以提高患者的依从性。另一个目的是研究在较高pH下的药物释放,这是由于频繁施用水以使剂型漂浮而引起的。含有(1)甲氨蝶呤-抗肿瘤药,(2)酪蛋白-乳化剂的多孔微球,通过乳化萃取方法在界面处混入气泡,以及(3)果胶-聚合物,并通过pH 4.0评估胃的滞留和控释特性。通过32全因子设计评估了各种工艺变量对粒径,浮力%和药物截留率的影响,并通过两种方差分析和多项式回归方法得出结论。过程变量对所有因变量都有相当大的影响。发现微球的形状规则,表面粗糙。微球制剂M9的粒径为59.60±0.95μm,浮力为82.0±0.27%,药物截留率为97.54±0.53%。通过PCP disso vi软件计算得出的结果进行了体外药物释放研究,结果显示最适合M9的模型为Korsmayer Peppas模型,并以Fickian方式释放药物。 KATO III胃细胞系的体外细胞毒性研究表明,与纯药物溶液相比,甲氨蝶呤微球对细胞系具有更大的细胞毒性作用。使用白化病小鼠进行的体内伽玛闪烁显像研究显示,上消化道保留了8小时以上

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号